H1 2021: Tecan reports substantial double-digit growth in sales and more than a doubling in net profit – on top of an already strong performance in the prior-year period
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules
Financial results for the first half of 2021
- Order entry increased to CHF 449.6 million (H1 2020: CHF 374.0 million)
- Increase of 20.9% in local currencies or 20.2% in Swiss francs
- Sales of CHF 454.0 million (H1 2020: CHF 310.0million)
- Growth of 47.5% in local currencies or 46.5% in Swiss francs
- Both business segments with similar growthrates
- Reported operating profit before depreciation and amortization (EBITDA) of CHF 115.0 million (H1 2020: CHF 60.2million)
- Reported EBITDA margin of 25.3% (H1 2020: 19.4%)
- Reported net profit of CHF 82.6 million(H1 2020: CHF 36.0million)
- Reported earnings per share increased by 127.8% to CHF 6.88 (H1 2020: CHF 3.02)
- Outlook for organic full-year sales and reported EBITDA margin raised
Operating highlights in the first half of 2021
- Launch of new variants of the Fluent® Automation Workstation to solve specific needsin key research and diagnostic applications
- Introduced important new reagent and digital offerings
- Tecan one of the first companies to meet the new requirements of the European Union’s In Vitro Diagnostic Regulation (IVDR), successfully completing first product certification
- Tecan ranked among Switzerland’s Best Large Workplaces™ by Great Place to Work® Switzerland
- Tecan expands its commercial reach, its capabilities and its US and Asia presence with the acquisition of Paramit Corporation(completed on August 2, 2021)
Männedorf, Switzerland, August 18, 2021 – The Tecan Group (SIX Swiss Exchange: TECN) posted a substantial double-digit increase in sales and more than a doubling in net profit in the first half of 2021. This builds on an already strong performance in the prior-year period.
Tecan CEO Dr. Achim von Leoprechting commented: “Tecan achieved outstanding sales and profit growth in the first half of the year, and I am incredibly proud of our employees, who support our customers with great commitment and passion. We still saw a strong sales contribution from product lines helping with the global response to COVID-19. However, in terms of order entry, this was outpaced by demand for products for other research and clinical applications. In particular, we are seeing strong momentum in automation systems as customers – in a reaction to the pandemic – seem to be placing more emphasis on keeping labs operational also in a hybrid working model with fewer personnel. This new aspect complements productivity and reproducibility, the traditional main advantages and value propositions of automation.
With the acquisition of Paramit Corporation successfully closed early August 2021, we look forward to working alongside our new colleagues at Paramit to scale innovation from research and diagnostics now all the way to the clinic.”
Financial results for the first half of 2021
Order entry increased by 20.9% in local currencies or 20.2% in Swiss francs to CHF 449.6 million in the first six months of the year (H1 2020: CHF 374.0 million). The company continued to see strong order entry for consumables to support the global fight against the coronavirus pandemic and, as expected, to a lesser extent for new instruments used for COVID-19 testing. In contrast to the two previous 6-month reporting periods, orders for products for other research and clinical applications were at a significantly higher level and exceeded pandemic-related orders.
Sales climbed by 47.5% in local currencies or 46.5% in Swiss francs to CHF 454.0 million in the first half of the year (H1 2020: CHF 310.0 million). Based on the high order backlog at year-end 2020 and new orders, Tecan continued to book significant pandemic-related sales for instruments, components and consumables. As with order entry, sales in the first half of 2021 also benefited significantly from a recovery and a more positive market environment in areas that were negatively impacted by the pandemic, such as life science research, pharma and non-COVID-19 diagnostic testing. Both business segments contributed almost equally to the overall sales growth in the first six months of the year.
Recurring sales of services, consumables and reagents increased in the first half of 2021 by 37.6% in local currencies and 35.4% in Swiss francs. With even higher growth rates for instruments, recurring sales accounted for 43.1% of total sales compared to 46.6% in the same period last year.
The reported operating profit before depreciation and amortization (earnings before interest, taxes, depreciation and amortization; EBITDA) rose to CHF 115.0 million in the reporting period (H1 2020: CHF 60.2 million). With an increase of 91.1%, reported EBITDA grew significantly faster than sales, mainly driven by benefits of scale due to the significantly increased volumes and a favorable product mix of instruments as well as a higher contribution from consumables and spare parts. The results development was also helped by a one-time positive effect from an adjustment of the Swiss pension plan (CHF 7.0 million). However, the company is assessing alternative pension schemes that could require a reversal of this gain in the second half of the year.
The reported EBITDA margin grew correspondingly by 590 basis points to 25.3% of sales (H1 2020: 19.4%).
Reported net profit in the first half of 2021 more than doubled to CHF 82.6 million (H1 2020: CHF 36.0 million). Reported net profit increased in line with operating profit (earnings before interest and taxes; EBIT). The reported net profit margin amounted to 18.2% of sales (H1 2020: 11.6%), while basic earnings per share rose to CHF 6.88 (H1 2020: CHF 3.02).
Cash flow from operating activities increased by 34.5% to CHF 111.4 million in the first half of 2021 (H1 2020: CHF 82.8 million), corresponding to 24.5% of sales (H1 2020: 26.7%).
Information by business segment
Life Sciences Business (end-customer business)
Sales in the Life Sciences Business increased by 47.8% to CHF 250.4 million (H1 2020: CHF 169.4 million) in the first half of the year and were 49.5% above the prior-year period in local currencies. Based on the high order backlog at year-end 2020, the Life Sciences Business continued to see a strong revenue contribution from products supporting the COVID-19 response, mainly liquid handling and automation workstations and associated disposable pipette tips. Segment sales in the first half of 2021 also benefited significantly from a recovery in areas that were negatively impacted by the pandemic, including liquid handling and automation workstations for various life science research applications, detection instruments and research reagents for next-generation sequencing (NGS).
Order entry in the Life Sciences Business grew with a strong double-digit rate in the first half of the year. The increase in order entry was mainly driven by strong momentum in automation systems for a wide variety of applications, detection instruments as well as continued substantial demand for consumables used for COVID-19 testing.
Reported operating profit in this segment (earnings before interest and taxes; EBIT) rose by 180.9% to CHF 63.1 million (H1 2020: CHF 22.5 million). The operating profit margin increased to 22.8% of sales (H1 2020: 12.6%). This positive performance is primarily a result of sales growth as well as a strong margin contribution from the consumables business.
Partnering Business (OEM business)
The Partnering Business generated sales of CHF 203.7 million in the period under review (H1 2020: CHF 140.6 million), which corresponds to an increase of 44.8% in Swiss francs and 45.1% in local currencies. Similar patterns to the Life Sciences Business were observed in the Partnering Business, with automation platforms, OEM components and disposable pipette tips supporting COVID-19 testing contributing strongly to sales as orders were converted from the high backlog into sales. Sales to customers in other areas of in-vitro diagnostics, which were negatively affected during the pandemic, also showed positive momentum again.
With the shift in order entry from COVID-driven applications to non-infectious disease customers, order entry in the Partnering Business also grew at a strong double-digit rate.
Operating profit in this segment (earnings before interest and taxes; EBIT) increased by 86.9% to CHF 49.2 million (H1 2020: CHF 26.3 million), while the operating profit margin grew to 24.0% of sales (H1 2020: 18.6%). Main drivers for the increase in profitability were benefits of scale due to the significantly higher volumes and a favorable product mix.
In Europe, Tecan’s sales in the first six months of 2021 increased by 36.1% in local currencies and by 38.3% in Swiss francs. Both business segments grew with a double-digit rate, the Partnering Business with 13.4% in local currencies and the Life Sciences Business with 59.0%.
In North America, sales rose by 69.4% in local currencies and by 62.0% in Swiss francs. The Life Sciences Business increased sales in the first six months of 2021 by 61.1% in local currencies. In the Partnering Business sales rose by 80.8%, despite the high comparative basis from the prior-year period.
In Asia, Tecan generated an increase in sales of 30.9% in local currencies and 33.7% in Swiss francs. Both segments contributed to the sales growth in the region with double-digit rates, the Life Sciences Business with growth in local currencies of 8.6% and the Partnering Business with 59.7%. In the first half of this year, the Chinese market environment returned to normal levels. Business in China had already benefited significantly from pandemic-related sales growth in the prior-year period. Tecan continued to record solid sales growth in the first half of 2021, although this was lower than in the Asia region as a whole due to the high comparison base.
Operating highlights in the first half of 2021
To further drive its application-focused strategy, Tecan continued to launch new variants of the leading Fluent Automation Workstation for key research and diagnostic applications. The Fluent Mix and Pierce Workstation provides end-to-end automation for whole blood pipetting in clinical environments. This newly developed instrument configuration is intended to standardize pre-analytical sample handling and mixing for consistent and scalable blood sampling and reduces the risk of laboratory staff coming into contact with infectious materials. Another example is the Frida Reader™ for Fluent that was launched earlier this year. It offers researchers the ability to quantify nucleic acids without sample loss. This unique solution performs UV absorbance-based quantification and purity assessment in a hanging drop, avoiding the consumption of rare and precious samples following nucleic acid purification (NAP).
Tecan also introduced new important reagent and digital offerings. New reagent kits for example enable end-to-end processing of human samples to allow complete viral RNA-Seq library preparation in a single day. New offerings in Tecan’s growing digital ecosystem include the development of a fully integrated, sample-to-result solution for PCR workflows together with laboratory software specialist UgenTec and the FluentControl Scheduler for the Fluent Automation Workstation. The FluentControl Scheduler is a new software that offers a number of features designed to simplify day-to-day laboratory automation for significantly increased throughput and workflow efficiency, streamlining workflows for laboratories that run various assays and processes in parallel.
At the beginning of the year, Tecan has become one of the first companies to meet the requirements of the European Union’s In Vitro Diagnostic Regulation (IVDR) 2017/746 (Annex IX, Chapter I and III), successfully completing certification of its IBL International DHEA Saliva ELISA diagnostic assay kit through BSI Notified Body 2797. The valuable insights gained from this process will now be applied to the registration of Tecan’s complete portfolio of specialty IVD products – as well as to help its OEM partners ensure they are ‘IVDR ready’ – ahead of the May 2022 transition deadline. The new IVDR represents a major regulatory overhaul, requiring reclassification and certification of all EU-registered IVD assays and devices.
Tecan firmly believes that a trust-based, purpose-driven, diverse and inclusive workplace culture makes a crucial difference in helping the company to become an even more successful business in the long term. In order to continue to improve in a targeted manner, for the first time in 2020 Tecan conducted the TrustIndex™ employee survey by the international research and consulting company Great Place to Work®. As a result of this survey and an additional in-depth Culture Audit™, Tecan has been officially certified as a Great Place to Work in January. Moreover, Tecan was ranked one of Switzerland’s Best Workplaces in the Large Company category (more than 250 employees) in May.
Acquisition of Paramit Corporation
On June 23, Tecan announced that it had entered into a definitive agreement to acquire US-based Paramit Corporation and its affiliates (“Paramit”) for a total purchase consideration of USD 1.0 billion (CHF 920 million). Paramit, headquartered in Morgan Hill (CA), US, is a leading OEM developer and manufacturer of medical devices and life sciences instruments. With the addition of approximately USD 300 million in revenues (CHF 276 million) expected in 2022, the acquisition will further extend Tecan’s position in solutions for life sciences and in-vitro diagnostics (IVD). It will also add a new business vertical in the attractive and fast-growing market for medical devices. The acquisition will bring significant engineering as well as cost-competitive manufacturing capabilities, both in North America and in the APAC region. Equipped with proprietary computer-directed assembly technology, these facilities deliver ultra-flexible production planning, while reducing the potential for errors (“zero-defect manufacturing”).
The acquisition of Paramit was successfully completed on August 2, 2021.
Strong balance sheet – high equity ratio
Tecan’s equity ratio was 69.6% as of June 30, 2021 (December 31, 2020: 66.2%). Net liquidity (cash and cash equivalents plus short-term time deposits minus bank liabilities and loans) increased to CHF 534.4 million (June 30, 2020: CHF 354.0 million; December 31, 2020: CHF 467.7 million).
At the Tecan Group Annual General Meeting on April 13, 2021, shareholders approved an increase in the dividend from CHF 2.20 to CHF 2.30 per registered share. Half of the dividend, i.e., CHF 1.15, was paid out from the available capital contribution reserve and was therefore not subject to withholding tax.
Organic outlook for full-year 2021raised
Based on the positive business performance in the first six months of 2021, as well as on the continued high order backlog and the anticipated demand in the second half of the year, Tecan raised its organic outlook for full-year 2021. Tecan continues to benefit from exceptional demand for COVID-19 related products and demand trends for these products remain subject to greater uncertainty.
Tecan now forecasts organic sales growth for full-year 2021 to be in the low to mid-teens percentage range in local currencies (previously “mid single-digit to mid-teens percentage range”).
At the same time, excluding acquisition-related effects, Tecan now expects a reported EBITDA margin in fiscal year 2021 of at least 23% of sales (previously “at least at the 2020 level of 21.8% of sales”).
The expectations regarding profitability are based on an average exchange rate forecast for full year 2021 of one euro equaling CHF 1.08 (unchanged) and one US dollar equaling CHF 0.90 (unchanged).
Impact of the acquisition of Paramit Corporation on Tecan’s 2021 financial results
The acquisition of Paramit Corporation was successfully completed and from August 1, 2021, Paramit will be included in the consolidated financial statements of the Tecan Group as a part of the Partnering Business segment.
Tecan expects that Paramit will generate additional sales of around CHF 100 million and an additional EBITDA, before acquisition-related costs, of about CHF 18 million in the five months of August to December 2021.
Initial integration and transaction costs (including hedging costs and various fees) are expected to amount to approximately CHF 20 million in 2021.
Financial Report and Webcast
The full 2021 Interim Report can be accessed on the company’s website www.tecan.com under Investor Relations.
Tecan will hold a conference call to discuss the results in the first half of 2021 today at 9:00 a.m. (CEST). The presentation will also be relayed by live audio webcast, which interested parties can access at www.tecan.com. A link to the webcast will be provided immediately prior to the event.
The dial-in numbers for the conference call are as follows:
For participants from Europe: +41 (0)58 310 50 00 or +44 (0)207 107 0613 (UK)
For participants from the US: +1 (1) 631 570 5613
Participants should if possible dial in 15 minutes before the start of the event.
Key upcoming dates
- The 2021 Annual Report will be published on March 15, 2022.
- The Annual General Meeting of Tecan’s shareholders will take place on April 12, 2022.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2020, Tecan generated sales of CHF 731 million (USD 778 million; EUR 683 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer19.9.2021 13:30:00 CEST | Press release
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting2 Kisqali plus letrozole achieved median OS of over five years (63.9 months), a survival benefit of over 12 months vs. placebo plus letrozole in postmenopausal women (HR=0.76; p=0.004)2 Kisqali is the only CDK4/6 inhibitor with proven OS benefit across all three Phase III trials of the MONALEESA program with different endocrine therapy partners, regardless of menopausal status or line of therapy2-4 MONALEESA-2 OS data to be presented at ESMO Congress 2021 as a late-breaker in an oral session The digital press release with multimedia content can be accessed here: Basel, September 19, 2021 — Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combinati
Hypefactors announces launch of 4th generation Reputation AI18.9.2021 10:37:51 CEST | Press release
Copenhagen, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Announcement no. 13-2021 Inside Information Copenhagen, 18. September 2021 The SaaS company Hypefactors, that delivers a unified solution for media intelligence and reputation tracking, will launch its next generation Reputation AI (artificial intelligence) on September 20, 2021. Through algorithmic advances in machine learning, as well as drastically increased data curated by a team of in-house recruited linguists with diverse language and cultural backgrounds, Hypefactors incorporates the latest scientific advances in natural language processing to deliver unprecedented accuracy, precision and automation to commercial end-users. AI-assisted reputation tracking is a core feature of Hypefactors and enables large scale tracking from social media, news websites, tv, radio and reviews across the world. These real-time reputation insights can reveal early-stage opportunities (e.g. GameStop media hype), and/or defensively as an on-going protect
Repurchase of shares in Millicom17.9.2021 23:00:00 CEST | Press release
Repurchase of shares in Millicom Luxembourg, September17, 2021 - During the period September 9, 2021 – September 15, 2021, Millicom repurchased a total of 131,559 of its Swedish Depository Receipts (SDRs), hereinafter referred to as shares within the framework of the repurchase program announced on July 29, 2021, details of which are shown in the table below. DateNumber of shares repurchasedWeighted average repurchaseprice (SEK) excluding commissionsTotal daily transaction value (SEK), excluding commissions 09/09/2021 15,000 322.6863 4,840,294.50 10/09/2021 30,000 322.1097 9,663,291.00 13/09/2021 17,974 322.3942 5,794,713.35 14/09/2021 15,725 321.5394 5,056,207.07 15/09/2021 52,860 314.4509 16,621,874.57 All purchases were carried out on Nasdaq Stockholm by Citigroup Global Markets Limited on behalf of Millicom. Following the purchases, as of September 15, 2021, Millicom holds 792,425 treasury shares. The total number of shares outstanding in Millicom is 101,739,217. The repurchase pro
Palette Life Sciences lanserar ny varumärkeswebbplats med USA:s portfölj17.9.2021 18:09:14 CEST | Pressemelding
Varumärkesuppdatering för USA och globala kommersiella produkter för behandling av ouppfyllda medicinska behov SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett helt integrerat globalt företag inom biovetenskap som arbetar för att förbättra patientutfall, lanserade idag sin nyligen uppdaterade webbplats Palettelifesciences.com. Webbplatsen har ett uppdaterat företagsvarumärke som stöder alla produkter i Palette Life Sciences-portföljen, och som fokuserar på minimalt invasiva behandlingar inriktade på ouppfyllda medicinska behov vid strålbehandling och interventionella onkologiska ingrepp, urologiska/urogynekologiska sjukdomar och kolorektala tillstånd. ”Vi inom Palette är stolta över vår förstklassiga produktportfölj som ger hopp åt dem med ouppfyllda medicinska behov”, säger Per G. Langö, Chief Executive Officer och Board Director för Palette Life Sciences. ”När vi bytte varumärke på vår webbplats övervägde vi hur vi bäst
Prosafe SE: bp charters Safe Zephyrus in 202217.9.2021 17:40:15 CEST | Press release
BP Exploration Operating Company Limited ('bp') has chartered the Safe Zephyrus to provide gangway connected operations to support the Seagull project at the ETAP central processing facility in the UK North Sea. The firm duration of the contract, starting Q1 2022, is 10 months with up to four months of options. The Safe Zephyrus is one of the world's most advanced and versatile accommodation vessels, complying with stringent rules in both UK and Norway and with a strong focus on reducing emissions by optimising the engine load. The value of the contract firm duration is USD 35.5 million, and the firm duration including options value is USD 49.3 million. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com 17 September 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-23BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 520, SE0014694659, 2027-09-15 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-09-23Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 146: 700 mln SEK +/-350 mln SEK 581: 500 mln SEK +/-250 mln SEK 520: 600 mln SEK +/-300 mln SEK 2312: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 400 mln SEK per bid 1591: 1900 mln SEK per bid 146: 700 mln SEK per bid 581: 500 mln SEK per bid 520: 600 mln SEK per bid 2312: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 16:20:00 CEST | Press release
Bid procedure, 2021-09-24BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2021-09-24Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 500 mln SEK +/-250 mln SEK 1053: 750 mln SEK +/-350 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 500 mln SEK per bid 1053: 750 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-28Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-09-17 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c